ABAT and non-small cell lung carcinoma: Additionally, Kaplan-Meier analysis of TCGA and microarray datasets (209459_s_at and 209460_at) indicated that NSCLC patients with low ABAT levels had poorer survival prognoses, aligning with our findings (Fig. 7b-c).